Switching between TNFα antagonists in rheumatoid arthritis: personal experience and review of the literature

The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not re...

Full description

Saved in:
Bibliographic Details
Published inReumatismo Vol. 61; no. 2; pp. 107 - 117
Main Authors Scrivo, R., Conti, F., Spinelli, F.R., Truglia, S., Magrini, L., Di Franco, M., Ceccarelli, F., Valesini, G.
Format Journal Article
LanguageEnglish
Italian
Published Pavia PAGEPress Publications 01.01.2009
Subjects
Monoclonal antibodies
Rheumatoid arthritis
Tumor necrosis factor-TNF
Online AccessGet full text

Cover

More Information
Summary:The treatment of rheumatoid arthritis (RA) has evolved over the past decade with the introduction of anti-tumor necrosis factor (TNF) α agents, which allowed remarkable advances in controlling signs and symptoms of inflammation and in slowing joint destruction (1-3). However, some patients do not respond or show suboptimal response to the currently available anti- TNFα agents (infliximab, etanercept, and adalimumab) used either as monotherapy or in combination with methotrexate. Furthermore, patients who respond initially may lose efficacy over time (4) or develop adverse events.
ISSN:0048-7449
2240-2683
DOI:10.4081/reumatismo.2009.107